Alcon On Track To Submit Anecortave NDA By Year-End Despite Study Disappointment
This article was originally published in The Pink Sheet Daily
Executive Summary
Anecortave, in development for wet age-related macular degeneration, failed to reach its primary non-inferiority endpoint in a comparative study with Novartis/QLT’s Visudyne. Alcon is studying a device to control drug reflux that it believes may improve patient outcomes.
You may also be interested in...
Alcon's Retaane Is Again "Approvable" For Wet AMD; Firm May Pursue Risk Reduction Indication Instead
FDA approval would require another trial, but "given the market and given what we know about the compound, we are not planning on initiating an additional study," firm tells "The Pink Sheet" DAILY.
Alcon's Retaane Is Again "Approvable" For Wet AMD; Firm May Pursue Risk Reduction Indication Instead
FDA approval would require another trial, but "given the market and given what we know about the compound, we are not planning on initiating an additional study," firm tells "The Pink Sheet" DAILY.
Industry Has Eye For Ophthalmic Uses Of Angiogenesis Inhibitors
New approaches to controlling blood vessel overgrowth, pioneered in oncology, are transforming retinopathy research. Two of the most advanced agents, Pfizer/Eyetech's Macugen and Genentech's Lucentis, block VEGF activity, while Alcon's Phase III candidate Retaane acts later in the angiogenic cascade. Small interfering RNA and gene therapy would work earlier, stopping production of angiogenic factors.